Mornex 2003

Methods	RCT: enrolled: 76 evaluated: 76
Participants	Inclusion: 1. histologically confirmed malignant melanoma 2. at least one measurable, non‐resectable cerebral lesion 3. age 18 to 70 years 4. life expectancy greater than three months 5. adequate blood counts 6. satisfactory liver and renal function 7. no previous chemotherapy within last four weeks 8. No previous cranial irradiation 9. Informed consent
Interventions	fotemustine versus fotemustine and WBRT
Outcomes	1. cerebral response rates (complete and partial) and control rate (complete, partial and stable disease) and time to cerebral progression on day 50 2. overall response rate, time to overall progression, overall survival
Notes	QS = 1